RT Journal Article
SR Electronic
T1 Whole genome sequencing association analysis of quantitative red blood cell phenotypes: the NHLBI TOPMed program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.09.20246736
DO 10.1101/2020.12.09.20246736
A1 Yao Hu
A1 Adrienne M. Stilp
A1 Caitlin P. McHugh
A1 Shuquan Rao
A1 Deepti Jain
A1 Xiuwen Zheng
A1 John Lane
A1 Sébastian Méric de Bellefon
A1 Laura M. Raffield
A1 Ming-Huei Chen
A1 Lisa R. Yanek
A1 Marsha Wheeler
A1 Yao Yao
A1 Chunyan Ren
A1 Jai Broome
A1 Jee-Young Moon
A1 Paul S. de Vries
A1 Brian D. Hobbs
A1 Quan Sun
A1 Praveen Surendran
A1 Jennifer A. Brody
A1 Thomas W. Blackwell
A1 Hélène Choquet
A1 Kathleen Ryan
A1 Ravindranath Duggirala
A1 Nancy Heard-Costa
A1 Zhe Wang
A1 Nathalie Chami
A1 Michael H. Preuss
A1 Nancy Min
A1 Lynette Ekunwe
A1 Leslie A. Lange
A1 Mary Cushman
A1 Nauder Faraday
A1 Joanne E. Curran
A1 Laura Almasy
A1 Kousik Kundu
A1 Albert V. Smith
A1 Stacey Gabriel
A1 Jerome I. Rotter
A1 Myriam Fornage
A1 Donald M. Lloyd-Jones
A1 Ramachandran S. Vasan
A1 Nicholas L. Smith
A1 Kari E. North
A1 Eric Boerwinkle
A1 Lewis C. Becker
A1 Joshua P. Lewis
A1 Goncalo R. Abecasis
A1 Lifang Hou
A1 Jeffrey R. O’Connell
A1 Alanna C. Morrison
A1 Terri H. Beaty
A1 Robert Kaplan
A1 Adolfo Correa
A1 John Blangero
A1 Eric Jorgenson
A1 Bruce M. Psaty
A1 Charles Kooperberg
A1 Russell T. Walton
A1 Benjamin P. Kleinstiver
A1 Hua Tang
A1 Ruth J.F. Loos
A1 Nicole Soranzo
A1 Adam S. Butterworth
A1 Debbie Nickerson
A1 Stephen S. Rich
A1 Braxton D. Mitchell
A1 Andrew D. Johnson
A1 Paul L. Auer
A1 Yun Li
A1 Rasika A. Mathias
A1 Guillaume Lettre
A1 Nathan Pankratz
A1 Cathy C. Laurie
A1 Cecelia A. Laurie
A1 Daniel E. Bauer
A1 Matthew P. Conomos
A1 Alexander P. Reiner
A1 the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
YR 2021
UL http://medrxiv.org/content/early/2021/01/05/2020.12.09.20246736.abstract
AB Whole genome sequencing (WGS), a powerful tool for detecting novel coding and non-coding disease-causing variants, has largely been applied to clinical diagnosis of inherited disorders. Here we leveraged WGS data in up to 62,653 ethnically diverse participants from the NHLBI Trans-Omics for Precision Medicine (TOPMed) program and assessed statistical association of variants with seven red blood cell (RBC) quantitative traits. We discovered 14 single variant-RBC trait associations at 12 genomic loci. Several of the RBC trait-variant associations (RPN1, ELL2, MIDN, HBB, HBA1, PIEZO1, G6PD) were replicated in independent GWAS datasets imputed to the TOPMed reference panel. Most of these newly discovered variants are rare/low frequency, and several are observed disproportionately among non-European Ancestry (African, Hispanic/Latino, or East Asian) populations. We identified a 3bp indel p.Lys2169del (common only in the Ashkenazi Jewish population) of PIEZO1, a gene responsible for the Mendelian red cell disorder hereditary xerocytosis [OMIM 194380], associated with higher MCHC. In stepwise conditional analysis and in gene-based rare variant aggregated association analysis, we identified several of the variants in HBB, HBA1, TMPRSS6, and G6PD that represent the carrier state for known coding, promoter, or splice site loss-of-function variants that cause inherited RBC disorders. Finally, we applied base and nuclease editing to demonstrate that the sentinel variant rs112097551 (nearest gene RPN1) acts through a cis-regulatory element that exerts long-range control of the gene RUVBL1 which is essential for hematopoiesis. Together, these results demonstrate the utility of WGS in ethnically-diverse population-based samples and gene editing for expanding knowledge of the genetic architecture of quantitative hematologic traits and suggest a continuum between complex trait and Mendelian red cell disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCore support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols for the Amish study were approved by the institutional review board at the University of Maryland Baltimore. Informed consent was obtained from each study participant. The BioMe cohort was approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai. All BioMe participants provided written, informed consent for genomic data sharing. All CARDIA participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Alabama at Birmingham and the University of Texas Health Science Center at Houston. All CHS participants provided informed consent, and the study was approved by the Institutional Review Board [or ethics review committee] of University Washington. All COPDGene participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. The Framingham Heart Study was approved by the Institutional Review Board of the Boston University Medical Center. All study participants provided written informed consent. All participants of GeneSTAR provided written informed consent and the study was approved by the Johns Hopkins Medicine Institutional Review Board. HCHS/SOL was approved by the institutional review boards (IRBs) at each field center, where all participants gave written informed consent, and by the Non-Biomedical IRB at the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State University. San Diego, CA. The JHS study was approved by Jackson State University, Tougaloo College, and the University of Mississippi Medical Center IRBs, and all participants provided written informed consent. All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. All SAFS participants provided informed consent, and the study was approved by Institutional Review Board at the University of Texas Rio Grande Valley. All WHI participants provided informed consent and the study was approved by the Institutional Review Board (IRB) of the Fred Hutchinson Cancer Research Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from TOPMed are available via dbGaP.